文章：

乳腺癌治疗：靶向与否？此乃关键问题

Breast Cancer Treatment: To tARget or Not? That Is the Question

原文发布日期：30 November 2023

DOI: 10.3390/cancers15235664

类型: Article

开放获取: 是

英文摘要：

To assess AR’s role in TNBC treatment, various existing and completed clinical trials targeting AR or co-targeting AR with other pertinent signaling molecules were analyzed. Cyclin-dependent kinase 4/6 (CDK4/6), cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17 lyase), and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway were some of the most prevalent biomarkers used in combination therapy with AR inhibitors in these trials. Studying how AR functions in tandem with these molecules can have increasing breakthroughs in the treatment options for TNBC. Previous studies have been largely unsuccessful in utilizing AR as the sole drug target for systemic targeted treatment in TNBC. However, there is a lack of other commonly used drug target biomarkers in the treatment of this disease, as well. Thus, analyzing the clinical benefit rate (CBR) within clinical trials that use combination therapy can prove to be imperative to the progression of improving treatment options and prognoses.

摘要翻译： 

为评估雄激素受体（AR）在三阴性乳腺癌（TNBC）治疗中的作用，本研究分析了多项针对AR或联合AR与其他相关信号分子的现有及已完成临床试验。在这些试验中，细胞周期蛋白依赖性激酶4/6（CDK4/6）、细胞色素P450 17α-羟化酶/17,20-裂解酶（CYP17裂解酶）以及磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（AKT）信号通路是与AR抑制剂联合治疗中最常用的生物标志物。深入研究AR与这些分子的协同作用机制，有望为TNBC治疗方案带来更多突破。既往研究已表明，将AR作为TNBC全身靶向治疗的单一药物靶点大多未能取得理想疗效，而该疾病治疗领域亦缺乏其他常用药物靶点生物标志物。因此，通过分析联合治疗临床试验中的临床获益率（CBR），对于推进治疗方案优化及改善预后具有至关重要的意义。

原文链接：

Breast Cancer Treatment: To tARget or Not? That Is the Question